Chapter 43: Engineering Antibodies with Preferred Antigen Specificity—References

Adams G.P. and Schier R. 1999. Generating improved single-chain Fv molecules for tumor targeting. J. Immunol. Methods 231: 249–260.

Altuvia Y., Schueler O., and Margalit H. 1995. Ranking potential binding peptides to MHC molecules by a computational threading approach. J. Mol. Biol. 249: 244–2450.

Balint R.F. and Larrick J.W. 1993. Antibody engineering by parsimonious mutagenesis. Gene 137: 109–118.

Bander N.H., Nanus D.M., Milowsky M.I., Kostakoglu L., Vallabahajosula S., and Goldsmith S.J. 2003. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin. Oncol. 30: 667–676.

Barbas C.F., Bain J.D., Hoekstra D.M., and Lerner R.A. 1992. Semisynthetic combinatorial antibody libraries: A chemical solution to the diversity problem. Proc. Natl. Acad. Sci. 89: 4457–4461.

Better M., Chang C.P., Robinson R.R., and Horwitz A.H. 1988. Escherichia coli secretion of an active chimeric antibody fragment. Science 240: 1041–1043.

Braunagel M. 2003. Construction of semisynthetic antibody libraries. Methods Mol. Biol. 207: 123–132.

Braunagel M. and Little M. 1997. Construction of a semisynthetic antibody library using trinucleotide oligos. Nucleic Acids Res. 25: 4690–4691.

Brekke O.H. and Sandlie I. 2003. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2: 52–62.

Burton D.R., Barbas C.F., Persson M.A., Koenig S., Chanock R.M., and Lerner R.A. 1991. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. 88: 10134–10137.

Cai X. and Garen A. 1995. Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: Selection of specific antibodies from single-chain Fv fusion phage libraries. Proc. Natl. Acad. Sci. 92: 6537–6541.

Dörsam H., Rohrbach P., Kürschner T., Kipriyanov S., Renner S., Braunagel M., Welschof M., and Little M. 1997. Antibodies to steroids from a small human naive IgM library. FEBS Lett. 414: 7–13.

Ghetie V. and Ward E.S. 2000. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu. Rev. Immunol. 18: 739–766.

Ghetie V., Popov S., Borvak J., Radu C., Matesoi D., Medesan C., Ober R.J., and Ward E.S. 1997. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat. Biotechnol. 15: 637–640.

Glennie M.J. and Johnson P.W. 2000. Clinical trials of antibody therapy. Immunol. Today 21: 403–410.

Honegger A. and Plückthun A. 2001. Yet another numbering scheme for immunoglobulin variable domains: An automatic modeling and analysis tool. J. Mol. Biol. 309: 657–670.

Hoogenboom H.R. and Chames P. 2000. Natural and designer binding sites made by phage display technology. Immunol. Today 21: 371–378.

Jones P.T., Dear P.H., Foote J., Neuberger M.S., and Winter G. 1986. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321: 522–525.

Khazaeli M.B., Conry R.M., and LoBuglio A.F. 1994. Human immune response to monoclonal antibodies. J. Immunother. 15: 42–52.

Kipriyanov S.M. 2004. Recombinant antibodies in infectious disease. Expert Opin. Ther. Patents 14: 135–140.

Kipriyanov S.M. and Le Gall F. 2004. Generation and production of engineered antibodies. Mol. Biotechnol. 26: 39–60.

Kjer-Nielsen L., Dunstone M.A., Kostenko L., Ely L.K., Beddoe T., Mifsud N.A., Purcell A.W., Brooks A.G., McCluskey J., and Rossjohn J. 2004. Crystal structure of the human T cell receptor CD3εγ heterodimer complexed to the therapeutic mAb OKT3. Proc. Natl. Acad. Sci. 101: 7675–7680.

Köhler G. and Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497.

Kretzschmar T. and von Rüden T. 2002. Antibody discovery: Phage display. Curr. Opin. Biotechnol. 13: 598–602.

Kuus-Reichel K., Grauer L.S., Karavodin L.M., Knott C., Krusemeier M., and Kay N.E. 1994. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin. Diagn. Lab. Immunol. 1: 365–372.

Little M., Welschof M., Braunagel M., Hermes I., Christ C., Keller A., Rohrbach P., Kurschner T., Schmidt S., Kleist C., and Terness P. 1999. Generation of a large complex antibody library from multiple donors. J. Immunol. Methods 231: 3–9.

Mark G.E. and Padlan E.A. 1994. Humanization of monoclonal antibodies. In The pharmacology of monoclonal antibodies (ed. M. Rosenberg and G.P. Moore), pp. 105–134. Springer-Verlag, Berlin.

Marks J.D., Tristem M., Karpas A., and Winter G. 1991a. Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. Eur. J. Immunol. 21: 985–991.

Marks J.D., Griffiths A.D., Malmqvist M., Clackson T.P., Bye J.M., and Winter G. 1992. By-passing immunization: Building high affinity human antibodies by chain shuffling. Biotechnology 10: 779–783.

Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., and Winter G. 1991b. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222: 581–597.

Nanus D.M., Milowsky M.I., Kostakoglu L., Smith-Jones P.M., Vallabahajosula S., Goldsmith S.J., and Bander N.H. 2003. Clinical use of monoclonal antibody HuJ591 therapy: Targeting prostate specific membrane antigen. J. Urol. 170: S84–S89.

Nissim A., Hoogenboom H.R., Tomlinson I.M., Flynn G., Midgley C., Lane D., and Winter G. 1994. Antibody fragments from a `single pot' phage display library as immunochemical reagents. EMBO J. 13: 692–698.

Padlan E.A. 1994. Anatomy of the antibody molecule. Mol. Immunol. 31: 169–217.

Pedersen J.T., Henry A.H., Searle S.J., Guild B.C., Roguska M., and Rees A.R. 1994. Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies. J. Mol. Biol. 235: 959–973.

Persson M.A., Caothien R.H., and Burton D.R. 1991. Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc. Natl. Acad. Sci. 88: 2432–2436.

Presta L. 2003. Antibody engineering for therapeutics. Curr. Opin. Struct. Biol. 13: 519–525.

Roguska M.A., Pedersen J.T., Keddy C.A., Henry A.H., Searle S.J., Lambert J.M., Goldmacher V.S., Blattler W.A., Rees A.R., and Guild B.C. 1994. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc. Natl. Acad. Sci. 91: 969–973.

Roguska M.A., Pedersen J.T., Henry A.H., Searle S.M., Roja C.M., Avery B., Hoffee M., Cook S., Lambert J.M., Blattler W.A., Rees A.R., and Guild B.C. 1996. A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing. Protein Eng. 9: 895–904.

Sambrook J. and Russell D.W. 2001. Molecular cloning: A laboratory manual, 2nd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.

Schier R., Bye J., Apell G., McCall A., Adams G.P., Malmqvist M., Weiner L.M., and Marks J.D. 1996a. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J. Mol. Biol. 255: 28–43.

Schier R., McCall A., Adams G.P., Marshall K.W., Merritt H., Yim M., Crawford R.S., Weiner L.M., Marks C., and Marks J.D. 1996b. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 263: 551–567.

Schueler-Furman O., Altuvia Y., Sette A., and Margalit H. 2000. Structure-based prediction of binding peptides to MHC class I molecules: Application to a broad range of MHC alleles. Protein Sci. 9: 1838–1846.

Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H., and Presta L.G. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277: 26733–26740.

Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., and Presta L.G. 2001. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 276: 6591–6604.

Skerra A. and Plückthun A. 1988. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240: 1038–1041.

Vaughan T.J., Williams A.J., Pritchard K., Osbourn J.K., Pope A.R., Earnshaw J.C., McCafferty J., Hodits R.A., Wilton J., and Johnson K.S. 1996. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol. 14: 309–314.

Welschof M., Terness P., Kipriyanov S.M., Stanescu D., Breitling F., Dörsam H., Dübel S., Little M., and Opelz G. 1997. The antigen-binding domain of a human IgG-anti-F(ab´)₂ autoantibody. Proc. Natl. Acad. Sci. 94: 1902–1907.

Welschof M., Terness P., Kolbinger F., Zewe M., Dübel S., Dörsam H., Hain C., Finger M., Jung M., Moldenhauer G., Hayashi N., Little M., and Opelz G. 1995. Amino acid sequence based PCR primers for amplification of rearranged human heavy and light chain immunoglobulin variable region genes. J. Immunol. Methods 179: 203–214.

Wild M.A., Xin H., Maruyama T., Nolan M.J., Calveley P.M., Malone J.D., Wallace M.R., and Bowdish K.S. 2003. Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat. Biotechnol. 21: 1305–1306.

<<< Chapter 42 References            Chapter 44 References >>>